Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

Gene Therapy

Volumn 7, Issue 9, 2000, Pages 726-733

  Wang, T L ^a   Ling, M ^a   Shih, I M ^a   Pham, T ^a   Pai, S I ^a   Lu, Z ^a   Kurman, R J ^a   Pardoll, D M ^a   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cervical cancer; Dendritic cell; E7; Human papillomaviruses (HPV); Immunity; Vaccines

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; WART VIRUS;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MURINAE; PAPILLOMAVIRUS;

EID: 0034061398     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301160     Document Type: Article

References (30)

1. Steinman RM. The dendritic cell system and its role in immunogenicity (review). Annu Rev Immunol 1991; 9: 271-296.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells (review). Curr Opin Immunol 1997; 9: 10-16.
3. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-3287.
4. Romani N et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989; 169: 1169-1178.
5. van Kooten C, Banchereau J. Functional role of CD40 and its ligand (review). Int Arch Allerg Immunol 1997; 113: 393-399.
6. Pierre P et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997; 388: 787-792.
7. Cella M et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-787.
8. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996; 183: 1287-1292.
9. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
10. Ossevoort MA et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emph Tumor Immunol 1995; 18: 86-94.
11. Mayordomo JI et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines (review). Stem Cells 1997; 15: 94-103.
12. Rouse RJ et al. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 1994; 68: 5685-5689.
13. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27: 2702-2707.
14. Arthur JF et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
15. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998; 91: 392-398.
16. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
17. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-715.
18. Yang S, Darrow TL, Vervaert CE, Seigler HF. Immunotherapeutic potential of tumor antigen-pulsed and impulsed dendritic cells generated from murine bone marrow. Cell Immunol 1997; 179: 84-95.
19. Ashley DM et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186: 1177-1182.
20. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723-2730.
21. Tatsuka M, Orita S, Yagi T, Kakunaga T. An improved method of electroporation for introducing biologically active foreign genes into cultured mammalian cells. Exp Cell Res 1988; 178: 154-162.
22. Lin KY et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
23. Feltkamp MC et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
24. Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A 'public' T-helper epitope of the E7 transforming protein of human papilloma virus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88: 5887-5891.
25. Morse MA et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59: 56-58.
26. Eggert AA et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59: 3340-3345.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
28. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation (review). Cell 1994; 76: 287-299.
29. Inaba K et al. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. 1: Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 1995; 163: 148-156.
30. Ji H et al. Targeting HPV-16 E7 to the endosomal lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 1999; 10: 2727-2740.